Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Acquired Immunodeficiency Syndrome: HELP
Articles by Yu Wang
Based on 7 articles published since 2009
(Why 7 articles?)
||||

Between 2009 and 2019, Yu Wang wrote the following 7 articles about Acquired Immunodeficiency Syndrome.
 
+ Citations + Abstracts
1 Editorial Towards ending HIV/AIDS among drug users in China. 2015

Wu, Zunyou / Wang, Yu / Detels, Roger / Bulterys, Marc. ·National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China. wuzy@263.net, wuzunyou@chinaaids.cn. ·Addiction · Pubmed #25533858.

ABSTRACT: -- No abstract --

2 Editorial China AIDS policy implementation: reversing the HIV/AIDS epidemic by 2015. 2010

Wu, Zunyou / Wang, Yu / Detels, Roger / Rotheram-Borus, Mary Jane. · ·Int J Epidemiol · Pubmed #21113031.

ABSTRACT: -- No abstract --

3 Clinical Trial A Model to Predict In-Hospital Mortality in HIV/AIDS Patients with Pneumocystis Pneumonia in China: The Clinical Practice in Real World. 2019

Wu, Liang / Zhang, Zhe / Wang, Yu / Hao, Yiwei / Wang, Fang / Gao, Guiju / Yang, Di / Xiao, Jiang / Zhao, Hongxin. ·Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, China. · The National Clinical Key Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, China. · Division of Medical Records and Statistics, Beijing Ditan Hospital, Capital Medical University, China. ·Biomed Res Int · Pubmed #30906778.

ABSTRACT: We aimed to develop and validate a predictive model to evaluate in-hospital mortality risk in HIV/AIDS patients with PCP in China. 1001 HIV/AIDS patients with PCP admitted in the Beijing Ditan hospital from August 2009 to January 2018 were included in this study. Multivariate Cox proportional hazard model was used to identify independent risk factors of death, and a predictive model was devised based on risk factors. The overall in-hospital mortality was 17.3%. The patients were randomly assigned into derivation cohort (801cases) and validation cohort (200 cases) in 8:2 ratio, respectively, in which in derivation cohort we found that 7 predictors, including LDH >350U/L, HR>130 times/min, room air PaO

4 Article A Clinical scoring model to predict mortality in HIV/TB co-infected patients at end stage of AIDS in China: An observational cohort study. 2019

Zhang, Zhe / Xu, Ling / Pang, Xiaoli / Zeng, Yongqin / Hao, Yiwei / Wang, Yu / Wu, Liang / Gao, Guiju / Yang, Di / Zhao, Hongxin / Xiao, Jiang. ·Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University. · The National Clinical Key Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University. · Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College. · Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Health Science Center, Beijing University. · Division of Medical Records and Statistics, Beijing Ditan Hospital, Capital Medical University. ·Biosci Trends · Pubmed #30930360.

ABSTRACT: We construct and validate a non-invasive clinical scoring model to predict mortality in HIV/TB patients at end stage of AIDS in China. There were 1,007 HIV/TB patients admitted to Beijing Ditan Hospital from August 2009 to January 2018 included in this study, who were randomly assigned to form derivation cohort and validation cohort. A clinical scoring model was developed based on predictors associated with mortality identified with Cox proportional hazard models. The discrimination and accuracy of model were further validated using the area under the ROC curves. The derivation and validation cohort consisted of 807 and 200 patients in 8:2 ratio, respectively. In derivation cohort, anemia (HGB < 90g/L), tuberculous meningitis, severe pneumonia, hypoalbuminemia, unexplained infections or space-occupying lesions, and malignancies remained independent risk factors of mortality in HIV/TB co-infected patients, and included in this clinical scoring model. The model indicated good discrimination, including AUC = 0.858 (95% CI: 0.782-0.943) in the derivation cohort, and AUC = 0.867 (95% CI: 0.832-0.902) in validation cohort, respectively. The predicted scores were categorized into two groups to predict the mortality: low-risk (0-2 points with mortality with 3.6-9.1%) and high-risk (4-16 points with mortality with 26.42-74.62%), in which 54.55% and 74.62% of patients with score of 5 to 11 and 12-16 were died among high-risk group. Kaplan-Meier curve indicated a significant difference in the cumulative mortality in the two groups by log-rank test (p < 0.001). A clinical scoring model to assess the prognosis in HIV/TB patients at end stage of AIDS was constructed based on simple laboratory and clinical features available at admission, which may be an easy-to-use tool for physicians to evaluate the prognosis and treatment outcome in HIV/TB co-infected patients. The model was also applicable for predicting the death of end-stage HIV/TB patients within a 12 months period after discharge.

5 Article [The treatment effect of immunoglobulin in AIDS with Guillain-Barre syndrome]. 2013

Zhang, Wen-Luo / Cao, Yue-An / Xia, Jing / Yang, Lu / Xie, Wen-Xiu / Wang, Yu / Peng, Chao-Sheng. ·Department of Special Medical Divison, Navy General Hospital, Beijing 100048, China. ·Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi · Pubmed #24319960.

ABSTRACT: OBJECTIVE: To discuss the treatment effect of immunoglobulin in acquired immune deficiency syndrome (AIDS) with Guillain-Barre syndrome (GBS). METHODS: The clinical data of AIDS with GBS, diagnosed by clinical and laboratory methods, were retrospectively analyzed, and literature retrieval analyzed. RESULTS: After treatment by immunoglobulin and antiviral. The patient's peripheral nerve injury recovered, and the number of HIV decreased. CONCLUSION: Immunoglobulin has a therapeutic effect for HIV infection related GBS, and beneficial to antiviral treatment.

6 Article Estimating the number of people living with HIV/AIDS in China: 2003-09. 2010

Wang, Ning / Wang, Lu / Wu, Zunyou / Guo, Wei / Sun, Xinhua / Poundstone, Katharine / Wang, Yu / Anonymous1470680. ·Chinese Center for Disease Control and Prevention, Beijing, China. ·Int J Epidemiol · Pubmed #21113033.

ABSTRACT: BACKGROUND: Before 2003, little was known about the scale of China's HIV/AIDS epidemic. In 2003, the Chinese government produced national estimates with support from the Joint United Nations Programme on HIV/AIDS, the World Health Organization and the United States Centers for Disease Control and Prevention. Subsequent national estimation exercises were carried out in 2005, 2007 and 2009. We describe these estimation processes and present the results of China's HIV/AIDS estimation exercises from 2003 to 2009. METHODS: The Workbook Method was used to generate national HIV/AIDS estimates. Data from the provincial level were used in 2003, data from the prefecture level were used in 2005 and data from the county level were used in 2007 and 2009. Data at the lowest level of aggregation were used to estimate risk group population size and HIV prevalence. Data from lower levels were combined into national estimates. RESULTS: At the end of 2003, 2005, 2007 and 2009, there were an estimated 0.84, 0.65, 0.70 and 0.74 million people living with HIV/AIDS in China, respectively, with an overall HIV prevalence of 0.05-0.06%. The number of new HIV infections decreased from 70 000 in 2005, to 50 000 in 2007, to 48 000 in 2009. Data quality improvements have increased the precision of China's HIV estimates. CONCLUSION: Repeated estimates have improved understanding of the HIV/AIDS epidemic in China. HIV estimates are a valuable tool for guiding national AIDS policies evaluating HIV prevention and control programmes.

7 Unspecified Introduction: China meets new AIDS challenges. 2010

Wu, Zunyou / Wang, Yu. ·National Center for AIDS/STD Control and Prevention, Beijing, China. ·J Acquir Immune Defic Syndr · Pubmed #20104098.

ABSTRACT: -- No abstract --